SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76755.05
715.06 (-0.92%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
61	Akums Drugs & Pharmaceuticals Ltd.	Q V PT	10,932 Small Cap	696.35 (0.26%)	97.92	4.5	10.00	11.58	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
62	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,509 Small Cap	4,611.30 (1.06%)	40.75	23.26	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
63	Jupiter Life Line Hospitals Ltd.	Q V PT	10,274 Small Cap	1,562.60 (-0.28%)	53.68	6.39	21.03	54.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
64	Healthcare Global Enterprises Ltd.	Q V+ PT	9,876 Small Cap	671 (1.44%)	677.39	6.15	13.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
65	Strides Pharma Science Ltd.	Q V+ PT	9,707 Small Cap	1,040.50 (-1.20%)	52.86	2.96	4.81	-16.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
66	Suven Life Sciences Ltd.	Q V+ PT	9,628 Small Cap	319.15 (-6.34%)	N/A	5.49	-14.30	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
67	Thyrocare Technologies Ltd.	Q V+ PT	8,944 Small Cap	558.40 (-0.62%)	54.73	15.45	10.88	8.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
68	Yatharth Hospital & Trauma Care Services Ltd.	Q V PT	8,260 Small Cap	851.70 (-0.65%)	86.58	5.1	27.90	137.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
69	Sanofi India Ltd.	Q V PT	7,784 Small Cap	3,403.50 (0.70%)	25.13	9.98	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
70	Sun Pharma Advanced Research Company Ltd.	Q V+ PT	7,290 Small Cap	213.95 (-4.76%)	4.7	5.47	49.34	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
71	Supriya Lifescience Ltd.	Q V+ PT	6,948 Small Cap	840.45 (-2.65%)	33.23	5.8	17.45	18.30	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
72	FDC Ltd.	Q V PT	6,735 Small Cap	409.80 (-0.94%)	23.56	2.7	9.23	1.32	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
73	Kovai Medical Center & Hospital Ltd.	Q V PT	6,491 Small Cap	5,748.40 (-3.10%)	26.55	4.92	14.01	17.17	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
74	Senores Pharmaceuticals Ltd.	Q V+ PT	6,471 Small Cap	1,394.25 (-0.78%)	319.57	8.63	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
75	Aarti Pharmalabs Ltd.	Q V+ PT	6,390 Small Cap	673.35 (-4.45%)	36.27	3.22	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
76	Nephrocare Health Services Ltd.	Q V+ PT	6,286 Small Cap	673.50 (7.74%)	N/A	6.6	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
77	Innova Captab Ltd.	Q V PT	5,605 Small Cap	974.65 (-0.48%)	66.97	6.32	25.90	14.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
78	Orchid Pharma Ltd.	Q V PT	5,183 Small Cap	1,001.45 (-2.01%)	114.65	3.78	13.89	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
79	Bliss GVS Pharma Ltd.	Q V+ PT	4,964 Small Cap	448.15 (-4.09%)	51.24	4.34	9.41	4.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
80	RPG Life Sciences Ltd.	Q V+ PT	4,906 Small Cap	3,005.50 (1.31%)	42.6	8.1	12.70	21.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
81	IOL Chemicals And Pharmaceuticals Ltd.	Q V+ PT	4,432 Small Cap	148.15 (-1.89%)	32.2	2.46	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
82	Artemis Medicare Services Ltd.	Q V+ PT	4,387 Small Cap	273.65 (-1.25%)	42.41	5.04	21.41	79.02	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
83	Novartis India Ltd.	Q V+ PT	4,196 Small Cap	1,699.05 (-0.02%)	45.03	5.13	-4.06	54.56	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
84	Unichem Laboratories Ltd.	Q V PT	4,125 Small Cap	527.80 (-9.92%)	25.96	1.57	4.67	-173.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
85	Gufic Biosciences Ltd.	Q V PT	3,992 Small Cap	386.25 (-2.98%)	63.22	6.01	16.69	24.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
86	Gujarat Themis Biosyn Ltd.	Q V+ PT	3,957 Small Cap	351.75 (-3.14%)	84.77	13.75	12.12	15.55	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
87	Aarti Drugs Ltd.	Q V PT	3,893 Small Cap	412.55 (-3.28%)	19.97	2.51	5.74	4.42	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
88	SMS Pharmaceuticals Ltd.	Q V+ PT	3,633 Small Cap	387.75 (-0.05%)	41.47	4.51	13.70	14.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
89	Advanced Enzyme Technologies Ltd.	Q V PT	3,599 Small Cap	312.95 (-2.64%)	27.31	5.14	9.82	13.51	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
90	Indraprastha Medical Corporation Ltd.	Q V+ PT	3,424 Small Cap	367.45 (-1.61%)	18.64	4.62	10.30	29.46	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Nephrocare Health	673.50	7.74%
Park Medi World	281.70	3.97%
Shree Ganesh Remed.	658	3.49%
GPT Healthcare	155.15	2.68%
Sigachi Industries	26.46	1.97%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Bajaj Healthcare	323.05	-12.70%
Unichem Laboratories	527.80	-9.92%
Marksans Pharma	240.90	-7.47%
Panacea Biotec	461.90	-6.60%
Suven Life Sciences	319.15	-6.34%

News about Top Pharma Companies in India

Jul, 2026

SMS Pharmaceuticals informs about newspaper publication

Pursuant to Regulations 30 and 47 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, SMS Pharmaceuticals has enclosed copies of the newspaper advertisement published on 22nd July, 2026, informing the shareholders about transfer of shares to Investor Education Protection Fund (IEPF) pertaining to the unpaid/ unclaimed dividend for the financial year 2018 -2019. The advertisement has been published in the following newspapers: Financial Express (in English language), Nava Telangana (in Telugu language). The newspaper advertisements are also made available on the website of the Company www.smspharma.com at Investors Section.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

SMS Pharmaceuticals informs about disclosure

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, SMS Pharmaceuticals has informed that a specimen of the reminder letter dispatched on 22th July, 2026 to the identified shareholders who have not claimed their dividends for seven or more consecutive years and whose shares are liable for transfer to the IEPF Authority, pursuant to Section 124(6) of the Companies Act, 2013 read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended from time to time, is being enclosed.

The above information is a part of company's filings submitted to BSE.

Jul, 2026

Gujarat Themis Biosyn informs about SAST disclosure

Gujarat Themis Biosyn has informed that it enclosed revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 20, 2026 for Themis Medicare.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Strides Pharma Science informs about record date

Strides Pharma Science has informed that the 35th Annual General Meeting ('AGM') of the Company will be held on Friday, August 14, 2026 at 12:15 hrs IST through Video Conferencing ('VC')/ Other Audio-Visual Means ('OAVM'), in compliance with the applicable circulars issued by the Ministry of Corporate Affairs ('MCA') and the Securities and Exchange Board of India ('SEBI'). As intimated earlier, Board of Directors of the Company at their meeting held on May 18, 2026 had recommended a Final Dividend of ?5/- per equity share of face value ?10/- each (50%) for the financial year ended March 31, 2026, subject to approval of the shareholders at the ensuing AGM. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Friday, July 31, 2026 as the Record Date for determining the entitlement of shareholders to receive the aforesaid Final Dividend: Final Dividend, if approved by shareholders at the ensuing AGM, shall be paid within 30 days from the date of its declaration, through permissible electronic modes to those shareholders whose bank account details are registered with the Depositories and/ or the Company's Registrar and Share Transfer Agent ('RTA'), subject to deduction of applicable taxes at source. Notice convening the AGM and the Annual Report for FY 2025-26 shall be filed separately with the Stock Exchanges and circulated to the shareholders within the prescribed timelines. The same shall also be made available on the website of the Company at www.strides.com and on the websites of BSE Limited and National Stock Exchange of India.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Sanofi India submits board meeting intimation

Sanofi India has informed that pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the meeting of the Board of Directors of Sanofi India is scheduled to be held on Tuesday, 4th August 2026 to consider and approve the Unaudited Financial Results for the quarter and half year ended 30th June 2026. Further, in reference to intimation dated 26th June 2026 for closure of trading window, they informed that the trading window for the purpose of publication of Unaudited Financial Results of the Company for the quarter and half year ended 30th June 2026 shall remain closed from Wednesday, 1st July 2026 till to Thursday, 6th August 2026.

The above information is a part of company's filings submitted to BSE.

Jul, 2026

Gujarat Themis Biosyn informs about disclosure

Gujarat Themis Biosyn has informed that the exchange has received disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 16, 2026 for Themis Medicare.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Sun Pharmaceutical Industries Ltd.	4,70,786 Crore
2	Divis Laboratories Ltd.	1,94,590 Crore
3	Torrent Pharmaceuticals Ltd.	1,91,658 Crore
4	Apollo Hospitals Enterprise Ltd.	1,28,265 Crore
5	Cipla Ltd.	1,15,728 Crore
6	Lupin Ltd.	1,14,967 Crore
7	Zydus Lifesciences Ltd.	1,14,080 Crore
8	Max Healthcare Institute Ltd.	1,07,094 Crore
9	Mankind Pharma Ltd.	1,06,460 Crore
10	Dr. Reddys Laboratories Ltd.	1,00,708 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	28,899	61,146	39.40	12.88	27.01	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,035	1,91,658	88.59	22.79	45.98	29.04
Lupin Ltd. (M)	Somewhat Good	2,406	1,14,967	21.56	5.14	12.47	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,459	44,698	42.33	9.88	28.59	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,589	67,940	31.09	4.85	22.55	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,578	86,059	92.06
Sai Life Sciences Ltd. (S)	Very Good	1,250	27,367	59.87
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,035	1,91,658	42.97
Aurobindo Pharma Ltd. (M)	Very Good	1,533	90,936	38.82
Lupin Ltd. (M)	Somewhat Good	2,406	1,14,967	30.85
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,250	27,367	80.14	10.91	42.14	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,459	44,698	42.33	9.88	28.59	13.54
Mankind Pharma Ltd. (M)	Very Good	2,544	1,06,460	52.25	6.51	32.71	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,130	1,14,080	22.63	4.39	13.85	13.52
Lupin Ltd. (M)	Somewhat Good	2,406	1,14,967	21.56	5.14	12.47	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,406	1,14,967	21.56	5.14	12.47	32.37
Abbott India Ltd. (M)	Very Good	28,899	61,146	39.40	12.88	27.01	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,183	1,00,708	24.00	2.67	13.45	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,130	1,14,080	22.63	4.39	13.85	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,943	4,70,786	41.01	5.63	23.51	14.41

You have 8 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

SMS Pharmaceuticals informs about newspaper publication

SMS Pharmaceuticals informs about disclosure

Gujarat Themis Biosyn informs about SAST disclosure

Strides Pharma Science informs about record date

Sanofi India submits board meeting intimation

Gujarat Themis Biosyn informs about disclosure

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.